NCT04296864

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Andover Eye Associates · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).

Conditions

• Atopic Keratoconjunctivitis

Interventions

Type	Name	Description
DRUG	Dupilumab	monoclonal antibody

Timeline

• Start date: 2020-02-10
• Primary completion: 2025-01-01
• Completion: 2025-01-01
• First posted: 2020-03-05
• Last updated: 2024-01-30

Locations

20 sites across 1 country: United States

Regulatory

• FDA-regulated drug study